GLP-1 Case Study Name: Richard J., a 58-year-old male Medical History: Type 2 Diabetes Mellitus (diagnosed 7 years ago) Obesity (BMI 35 kg/m) Hypertension (well-controlled on an ACE inhibitor) Mild diabetic retinopathy Current Medications: Metformin 1000 mg twice daily, glimepiride 2 mg once daily, and lisinopril 20 mg once daily Clinical Presentation Richard presents a routine follow-up
Treatment typically includes antifungal, keratolytic (scale-removing), anti-itch, and anti-inflammatory (steroid creams and calcineurin inhibitors) medications
Biological factors include: Starting body weight and BMI: Individuals with higher baseline weight may see larger absolute reductions, though percentage weight loss can vary
Sukumaran and colleagues treated Zucker lean and obese rates with either vehicle or the GLP-1 agonist liraglutide (LIRA) for 8 weeks [66]
Nausea, vomiting, diarrhoea and constipation may occur, particularly at higher doses or during dose increases as the body adjusts to treatment
